CommercialDocumentationMedium impact
08.01.52h, Mogamulizumab-kpkc (Poteligeo)
Independence Blue Cross·Oncology, Pharmacy·Pharmacy
Effective date
Sep 4, 2026
We identified it
Sep 5, 2026
Summary
Policy 08.01.52h for Mogamulizumab-kpkc (Poteligeo) has been updated effective 09/04/2026 with changes to medical necessity criteria and medical coding requirements. The billing team must review updated documentation and coding standards for this specialty pharmacy drug to ensure compliant claim submission.
Action Required
By September 4, 2026: Billing team must obtain and review the full policy text for 08.01.52h Mogamulizumab-kpkc (Poteligeo) from the source URL. Update billing system and clinical documentation templates to reflect new medical necessity criteria. Coordinate with oncology providers to ensure they document all required criteria before drug administration. Verify correct medical coding is applied to all Poteligeo claims. Without proper documentation of medical necessity criteria, claims will be denied.